DIAGNOS Announces the Engagement of Allele Capital Partners

Core Insights - Diagnos Inc. has engaged Allele Capital Partners for capital markets advisory and social media services to enhance its business strategy and shareholder value [1][3]. Group 1: Engagement Details - The agreement with Allele includes a monthly compensation of US$7,500 for the period from May 22, 2025, to August 22, 2025, with the option for DIAGNOS to terminate the agreement with 30 days' notice [2]. - After the initial trial period, the agreement can be renewed for an additional nine months at the same compensation rate, subject to written confirmation from DIAGNOS [2]. Group 2: Company Overview - DIAGNOS is focused on the early detection of critical eye-related health issues using advanced AI technology to improve diagnostic accuracy and patient outcomes globally [5]. - The company aims to provide healthcare clinicians with enhanced information to streamline workflows and optimize capital needs [3].